Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Trastuzumab and Pertuzumab in Older Women with HER2+ Metastatic Breast Cancer
NCT02000596Phase 2Terminated
- Sponsor
- University of Maryland, Baltimore
- Start
- Jan 2014
- Primary completion
- Nov 2015
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of pertuzumab, trastuzumab in breast cancer, sponsored by University of Maryland, Baltimore. Started Jan 2014; status: terminated.
02
Drugs
pertuzumabtrastuzumab
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT02000596.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02000596.